IL6 and rheumatoid arthritis: Preclinical studies have demonstrated that the Janus kinase (JAK) inhibitor pefixitinib effectively suppresses the inflammatory response induced by the tumor suppressor M and IL-6 trans-signaling in RA-SFs, as well as their proliferation and migration in vitro [136].